Literature DB >> 33002799

Immune checkpoint molecules on T cell subsets of pregnancies with preeclampsia and gestational diabetes mellitus.

Yuanyuan Zhao1, Xiaolu Zhang2, Ning Du3, Hong Sun4, Lei Chen2, Hongchu Bao5, Quan Zhao3, Qinglan Qu5, Ding Ma5, Joanne Kwak-Kim6, Wen-Juan Wang7.   

Abstract

Immune checkpoint molecules may play a crucial role in safeguarding pregnancy by regulating immune responses at the maternal-fetal interface. In this study, we aim to investigate the expression of PD-1, GITR, HLA-G, and CTLA-4 on T cell subsets in peripheral blood (PB), retroplacental blood (RPB), and cord blood (CB) in normal pregnancy (NP), preeclampsia (PE) and gestational diabetes mellitus (GDM). PB, RPB, and CB were collected immediately after delivery, and the expression of PD-1, GITR, HLA-G, and CTLA-4 on T cell subsets were measured by flow cytometric analysis. The proportions of Tregs in PB, RPB, and CB from NP were significantly higher than those of PE and GDM (P < 0.01, respectively). PD-1+ and GITR+ T cell subsets (CD3+, CD4+, and CD8+ T cells, and Tregs) in PB, as well as PD-1+ T cell subsets in RPB from NP, were significantly higher than those of PE and GDM (P < 0.01, respectively). In NP, PE, and GDM, the proportion of PD-1+ Tregs was significantly decreased in CB as compared to those of PB and RPB (P < 0.05, respectively) and the proportion of GITR+ Tregs was significantly higher in PB as compared to those of CB and RPB (P < 0.01, respectively). The proportion of HLA-G+ Tregs in PB was significantly lower than those of CB and RPB (P < 0.01, respectively). In conclusion, decreased PD-1+ and GITR+ T cell subsets and decreased proportion of Tregs in PB and RPB may play a role in chronic inflammatory immune activation of effector T cells in PE and GDM.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cord blood; Gestational diabetes mellitus; Peripheral blood; Preeclampsia; Regulatory T cells; Retro-placental blood

Year:  2020        PMID: 33002799     DOI: 10.1016/j.jri.2020.103208

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  6 in total

1.  Outcomes of Pregnancy During Immunotherapy Treatment for Cancer: Analysis of Clinical Trials Sponsored by the National Cancer Institute.

Authors:  Arjun Mittra; Abdul Rafeh Naqash; James H Murray; Shanda Finnigan; Joanne Kwak-Kim; S Percy Ivy; Alice P Chen; Elad Sharon
Journal:  Oncologist       Date:  2021-09-20       Impact factor: 5.837

Review 2.  Review of the immune mechanisms of preeclampsia and the potential of immune modulating therapy.

Authors:  Ai-Ris Y Collier; Laura A Smith; S Ananth Karumanchi
Journal:  Hum Immunol       Date:  2021-02-05       Impact factor: 2.850

Review 3.  Gestational Diabetes Mellitus and Maternal Immune Dysregulation: What We Know So Far.

Authors:  Colm J McElwain; Fergus P McCarthy; Cathal M McCarthy
Journal:  Int J Mol Sci       Date:  2021-04-20       Impact factor: 5.923

Review 4.  Regulation of the innate immune cells during pregnancy: An immune checkpoint perspective.

Authors:  Wen-Xuan Li; Xiang-Hong Xu; Li-Ping Jin
Journal:  J Cell Mol Med       Date:  2021-10-28       Impact factor: 5.310

Review 5.  The Role of the Immune Checkpoint Molecules PD-1/PD-L1 and TIM-3/Gal-9 in the Pathogenesis of Preeclampsia-A Narrative Review.

Authors:  Johanna Mittelberger; Marina Seefried; Manuela Franitza; Fabian Garrido; Nina Ditsch; Udo Jeschke; Christian Dannecker
Journal:  Medicina (Kaunas)       Date:  2022-01-20       Impact factor: 2.430

Review 6.  Immunological Changes in Pregnancy and Prospects of Therapeutic Pla-Xosomes in Adverse Pregnancy Outcomes.

Authors:  Himadri Devvanshi; Rohit Kachhwaha; Anima Manhswita; Shinjini Bhatnagar; Pallavi Kshetrapal
Journal:  Front Pharmacol       Date:  2022-04-20       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.